Chemotherapy prolongs survival in inoperable pancreatic carcinoma

DOI PDF Web Site 被引用文献5件
  • K R Palmer
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
  • M Kerr
    Gastrointestinal Unit, and Department of Clinical Oncology, Western General Hospital, Edinburgh, UK
  • G Knowles
    Gastrointestinal Unit, and Department of Clinical Oncology, Western General Hospital, Edinburgh, UK
  • A Cull
    Gastrointestinal Unit, and Department of Psychology, Western General Hospital, Edinburgh, UK
  • D C Carter
    Gastrointestinal Unit, and University Department of Surgery, The Royal Infirmary, Edinburgh, UK
  • R C F Leonard
    Gastrointestinal Unit, and Department of Clinical Oncology, Western General Hospital, Edinburgh, UK

抄録

<jats:title>Abstract</jats:title><jats:p>Forty-three patients with irresectable advanced pancreatic cancer were randomized to receive chemotherapy using a combination of 5-fluorouracil, Adriamycin and mitomycin or no chemotherapy. Groups were well matched with regard to age, extent of disease and performance status on entry. Chemotherapy was well tolerated and, although common, side-effects were usually mild. Psychological measurements based on the Hospital Anxiety and Depression score were made in 31 patients. These showed significantly less depression but not anxiety in the treated group immediately after randomization and following 2 months of chemotherapy. Median survival in the treated group was 33 (range 9–80) weeks compared with 15 (range 1–62) weeks in the untreated group (P &lt; 0·002). Chemotherapy should be considered in all patients presenting with advanced inoperable pancreatic cancer.</jats:p>

収録刊行物

被引用文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ